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Putative antagonists are thought to be useful agents for preventing neurodamage and treating cocaine abuse, schizophrenia, and other neurological disorders. 9 Furthermore, both σ 1 and σ 2 ligands are required as cancer diagnostic tools for positron emission tomography (PET) analysis. 6 The σ 1 gene is located on human chromosome 9, band p13, a region indeed known to be associated with different psychiatric disorders. 10 It encodes a unique protein consisting of 223 amino acids, which was first cloned and functionally expressed by Kekuda and colleagues. 11 From the structural standpoint, the only information available mostly concern the protein main structural motifs, which include an intracellular N-terminal end, two transmembrane spanning domains (residues 10À30 and 80À100) linked by an extracellular loop, and a partially arranged C-terminal end. 12 A typical arginineÀarginine endoplasmic reticulum locating signal near the N-terminal end has also been identified. Importantly, σ 1 receptors contain two GXXXG motifs, a signature that occurs with high frequency in membrane proteins that favor helixÀhelix interactions. 13 Because σ 1 is a membrane-bound protein, its expression, purification, crystallization, and structure determination are difficult processes. Thus, no information about the three-dimensional (3D) structure of the cloned σ 1 receptor has been released so far; this constitutes a serious hurdle in the development of new, potent ligands for this protein.
In this work, we present for the first time a 3D model for the σ 1 receptor based on a molecular modeling and simulation ansatz involving the following sequential steps: (i) generation and optimization of the complete 3D model of the receptor by homology modeling techniques; 14 (ii) further 3D homology model refinement exploiting information derived from ligand ABSTRACT: This study presents for the first time the 3D model of the σ 1 receptor protein as obtained from homology modeling techniques, shows the applicability of this structure to docking-based virtual screening, defines a computational strategy to optimize the results based on a combination of 3D pharmacophore-based docking and MM/PBSA free energy of binding scoring, and provides evidence that these in silico models and recipes are powerful tools on which virtual screening of new σ 1 ligands can be based. In particular, the validation of the applicability of docking-based virtual screening to homology models is of utmost importance, since no crystal structure is available to date for the σ 1 receptor, and this missing information still constitutes a major hurdle for a rational ligand design for this important protein target. 23 as spatial restraints; (iii) docking of a series of bioactive ligands into the putative binding site, estimation of their binding affinity via the molecular mechanics/PoissonÀ Boltzmann surface area (MM/PBSA) methodology, 24 and comparison with the available experimental activities;
19À22 and (iv) design of a set of new ligands with different degrees of affinity for the protein based on the derived receptor model to test the predictive capability of the σ 1 3D model. Detailed information about each single step mentioned above can be found in the Supporting Information.
The initial stage of step (i) consisted in the modeling of the transmembrane (TM) regions (three α-helices spanning residues 10À30, 80À100, and 180À200, respectively) and the prediction of the overall secondary structure of the protein, which included a few β-strands in the C-terminal half (residues 111À116, 133À135, 144À146, and 158À164), and some loops. The search for a suitable template to build the 3D receptor structure yielded four different protein sequences having both a considerable identity (g30%) with specific portions of the σ 1 sequence and an X-ray structure available in the Protein Data Bank (PDB entries 3CIA, 1I24, 2Z2Z, and 2Q8I) (see the Supporting Information, S3). Accordingly, each corresponding receptor/template sequence was aligned, and the Cartesian coordinates for σ 1 residues in structurally conserved regions were obtained from the corresponding sequence in the template PDB file. The first part of the N-terminal domain of the protein (residues 1À16) showed no homology with any other proteins in all queried databases and thus was built de novo. Finally, the overall receptor 3D structure was built, linking the different template-based homology models and creating/optimizing the missing loop portions via several refinement processes. The structure was slightly adjusted to fully match the results of secondary structure predictions and optimized for backbone and side chain conformation. This initial 3D model was then subjected to extensive molecular dynamics (MD) refinement first in explicit solvent to attain an energetically stable and favorable conformation (see the Supporting Information, S4). The MD-refined homology model (Figure 1a ), characterized by a very high stereochemical quality (more than 98% of residues in the favored or additional allowed regions of Ramachandran plot and only two residues in the disallowed region), was employed in the successive step.
Step (ii) required the initial identification of a putative binding site in the receptor model, based on preliminary information on sequenceÀ-structure relationships, 23 mutagenesis studies, 23 and some ligand-binding pharmacophore requirements (see Supporting Information, S5).
19À22 In detail, a protein isoform missing residues 119À149 was found devoid of ligand binding capacity, and the conversion of residues D126 and E172 to glycine led to a several-fold reduction in ligand-binding function for the σ 1 receptor. 23 Moreover, a hydrophobicity analysis performed in the present study identified, aside for the TM regions, a third hydrophobic region matching the SBDLII (steroid binding domain-like II) region and centered on Asp188, a residue specifically photolabeled by [ 
25,26
Having localized this protein region as a possible zone for ligand binding, a thorough search for a set of complementary protein residues satisfying the chemical features imposed by our 
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LETTER recently developed 3D pharmacophore model 19À22 was performed and successfully retrieved (see Figure S7 in the Supporting Information). Then, from a previously synthesized set of σ 1 ligands, 22 the lead compound 1c 22 was docked into the σ 1 putative binding pocket. In the set of docked ligand conformations, a solution was found that best reproduced the key interactions from 3D pharmacophore model as depicted in the derived topographical model (Figure 1b) . The resulting molecular complex was relaxed by energy minimization and MD simulations, and finally, a model without unfavorable van der Waals interactions was obtained (Figure 1c) . Figure 1d shows the ligand-binding site of the resulting σ 1 /1c complex, which retains the proposed interactions in the 2D topological model. Indeed, the interactions essential for the binding of ligand 1c are (1) a salt bridge between the 1c piperidine ÀNH + and the protein Asp126 ÀCOO -(first 3D pharmacophore requirement); (2) the hydrogen bond (HB) between the backbone ÀNH donor of the peptidic bond linking Thr151 and Val 152 on the receptor side and the acceptor oxygen atom of the benzoxazolone moiety of 1c (second 3D pharmacophore requirement); (3) T-stacking πÀπ interaction between the protein residue Trp121 and the heteroaromatic condensed rings of 1c (third 3D pharmacophore requirement); (4) parallel-stacking πÀπ interaction between the protein residue Tyr173 and the benzoxazolone phenyl ring of 1c (fourth 3D pharmacophore requirement); (5) highly stabilizing van der Waals and electrostatic interactions between Arg119 and Glu172 with the p-Cl-phenyl and the benzoxazolonic heterocycle of 1c, respectively; and (6) general hydrophobic favorable interactions between the side chains of Ile128, Thr151, and Val152 with both the aliphatic and the aromatic portions of the ligand.
In step (iii), the refined σ 1 homology model was used for the docking of a series of bioactive ligands (including 1c) into the putative binding site, estimation of their binding affinity via the MM/PBSA methodology, 24 and comparison with the available experimental activities (see the Supporting Information, S6).
19À22 Table 1 shows the results of the MM/PBSA ranking, from which the excellent agreement between computed and experimental affinities of these ligand series is apparent.
The quality of the model was further validated by probing its ability to accommodate other known σ 1 ligands belonging to structurally diverse compound classes. Thus, the strong σ 1 agonist pentazocine (PTZ) 27 and the two high-affinity σ 1 ligands fenpropimorph (FEN) 28 and haloperidol (HALO) 19 were docked into the σ 1 binding site and scored according to the same protocol employed for 1c and related compounds. Importantly, the adopted binding modes of these three compounds ( Figure 2) were also in agreement with the proposed 2D interaction model (Figure 1b) , and the MM/PBSA was able to rank their affinity not only in the correct order but also with an outstanding agreement between computed and experimental K i values 19, 29, 30 (R 2 = 0.93, see Figure S9 in the Supporting Information).
Lastly, in step (iv), all information presented above and the new 3D homology model derived in this work were exploited for the design of a new, small series of σ 1 ligands starting from the structure of the lead compound 1c. Subsequently, step (iii) of the multistep procedure outline above was applied to predict their affinity toward the protein. The rationale (see the Supporting Information, S7 and S8) behind this design was to check the predictive capabilities of the entire developed computational procedure and models in the design of novel σ 1 ligands. Under this perspective, three new compounds EL-1, EL-2, and EL-3 were conceived exploiting the developed 2D/3D interaction model ( Figure 3 ) and ranked as highly affine, moderately affine, and poorly affine to the σ 1 protein by our in silico procedure according to the ΔG bind values listed shown in Table 2 . Importantly, these predicted affinities were confirmed by the corresponding experimental values of binding constant K i , ultimately validating the predictive features of the present computational recipe. Of note, compound EL-1 exhibited a very promising K i value of 1.87 nM, in utter agreement with the MM/ PBSA predicted value of 5.20 nM. As shown in Figure 3 , compound EL-1 adopted a binding mode within the receptor putative binding pocket, which satisfies all proposed 2D/3D interaction models.
In conclusion, the multistep homology modeling procedure adopted in this work produced a reliable 3D structure of the σ 1 receptor that can successfully be employed as a platform for structure-based drug design. Overall, this work illustrates that explicit ligand information can be successfully employed to optimize the binding site model. This approach can be especially helpful when modeling proteins with highly flexible binding sites, or targets that are difficult to characterize experimentally, and/or pockets with low homology to available template structures, as in the present case of σ 1 receptors. A thorough model validation was performed by a docking/MMPBSA-based small-scale virtual screening and by the receptor model-based design of three new Figures 1b and 3b . The main protein residues involved in these interactions are Arg119 (red), Trp121 (cyan), Asp126 (blue), Ile128 (forest green), Thr151 (sienna), Val152 (orange), Glu172 (yellow), and Tyr173 (magenta). σ 1 ligands, featuring activity in a wide range. Although medicinal chemistry is still eager to obtain new X-ray structures of protein targets, this study with σ 1 receptor demonstrates that its derived 3D homology model is already an excellent substrate. Given the intense ongoing efforts in designing new compounds as potent σ 1 ligands, this work is rather an encouraging account.
' ASSOCIATED CONTENT b S Supporting Information. Detailed experimental and computational procedures, 3D pharmacophore features, chemical formulas and structures of discussed compounds, syntheses and characterization of compounds, pharmacology, and more modeling-derived information. This material is available free of charge via the Internet at http://pubs.acs.org.
